Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir
Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4+ lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinav...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1998-04, Vol.177 (4), p.898-904 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 904 |
|---|---|
| container_issue | 4 |
| container_start_page | 898 |
| container_title | The Journal of infectious diseases |
| container_volume | 177 |
| creator | Angel, Jonathan B. Kumar, Ashok Parato, Karl Filion, Lionel G. Diaz-Mitoma, Francisco Daftarian, Pirouz Pham, Ba' Sun, Eugene Leonard, John M. Cameron, D. William |
| description | Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4+ lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log10 copies/mL to below the detection limit of the assay (2.30 log10), and mean CD4+ lymphocyte count increased from 284 cells/mL to 413 cells/mL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8+ lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process. |
| doi_str_mv | 10.1086/515244 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_79772634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30108084</jstor_id><sourcerecordid>30108084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-e20a9b41ac7662aa543d74b5b9b76d1f2da08e9272bf2190cca3387b3a34338e3</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhgdR6lr1HwhBxLvRfGdyWZbWXakodS3iTchkMjbrTGabj-pe-8fNussWvPEqJzwP7-HlVNVzBN8g2PC3DDFM6YNqhhgRNeeIPKxmEGJco0bKx9WTGNcQQkq4OKlOJCNUcjSrfi_HTZju7Gh9As6DuR2G-oPtnE62A8txzN6Ci-xNcpMHXQ7OfwefprTTz3xy9SKP2u_FqbO9M856swXXLuQIVjc26M0W_HTpBly5NHl95wLYDIV91rfZ_f0_rR71eoj22eE9rb5cnK_mi_ry47vl_OyyNpSxVFsMtWwp0kZwjrVmlHSCtqyVreAd6nGnYWMlFrjtMZLQGE1II1qiCS2DJafV631uaXybbUxqdNGUwtrbKUclpBCYF_l_IuKUYcGbIr78R1xPOfhSQmFMJBQEyvs0E6YYg-3VJrhRh61CUO1up_a3K-KLQ1puR9sdtcOxCn914DoaPfRBe-PiUcMY8dLzPmYd0xSOmMCyCza7NfWeu5jsryPX4YfiggimFl-_KblikF7R9-qa_AHjB7lF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223907309</pqid></control><display><type>article</type><title>Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>Oxford Journals Online</source><creator>Angel, Jonathan B. ; Kumar, Ashok ; Parato, Karl ; Filion, Lionel G. ; Diaz-Mitoma, Francisco ; Daftarian, Pirouz ; Pham, Ba' ; Sun, Eugene ; Leonard, John M. ; Cameron, D. William</creator><creatorcontrib>Angel, Jonathan B. ; Kumar, Ashok ; Parato, Karl ; Filion, Lionel G. ; Diaz-Mitoma, Francisco ; Daftarian, Pirouz ; Pham, Ba' ; Sun, Eugene ; Leonard, John M. ; Cameron, D. William</creatorcontrib><description>Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4+ lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log10 copies/mL to below the detection limit of the assay (2.30 log10), and mean CD4+ lymphocyte count increased from 284 cells/mL to 413 cells/mL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8+ lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/515244</identifier><identifier>PMID: 9534961</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antigens ; Antiretrovirals ; Antiviral agents ; Biological and medical sciences ; Blood ; Blood plasma ; CD28 Antigens - immunology ; CD28 Antigens - metabolism ; CD4 Lymphocyte Count ; CD8-Positive T-Lymphocytes - immunology ; Cell Division ; Cytokines ; Drug Therapy, Combination ; Flow Cytometry ; HIV ; HIV - isolation & purification ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Protease Inhibitors - administration & dosage ; HIV Protease Inhibitors - therapeutic use ; Humans ; Immunity, Cellular ; Interleukin-10 - metabolism ; Interleukin-12 - metabolism ; Interleukin-2 - metabolism ; Leukocytes, Mononuclear - cytology ; Leukocytes, Mononuclear - immunology ; Lymphocytes ; Major Articles ; Medical sciences ; Pharmacology. Drug treatments ; Phytohemagglutinins - immunology ; Ritonavir - administration & dosage ; Ritonavir - therapeutic use ; RNA ; RNA, Viral - isolation & purification ; Saquinavir - administration & dosage ; Saquinavir - therapeutic use ; T lymphocytes ; Viral Load ; Viruses</subject><ispartof>The Journal of infectious diseases, 1998-04, Vol.177 (4), p.898-904</ispartof><rights>Copyright 1998 The University of Chicago</rights><rights>1998 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Apr 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-e20a9b41ac7662aa543d74b5b9b76d1f2da08e9272bf2190cca3387b3a34338e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30108084$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30108084$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2216338$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9534961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Angel, Jonathan B.</creatorcontrib><creatorcontrib>Kumar, Ashok</creatorcontrib><creatorcontrib>Parato, Karl</creatorcontrib><creatorcontrib>Filion, Lionel G.</creatorcontrib><creatorcontrib>Diaz-Mitoma, Francisco</creatorcontrib><creatorcontrib>Daftarian, Pirouz</creatorcontrib><creatorcontrib>Pham, Ba'</creatorcontrib><creatorcontrib>Sun, Eugene</creatorcontrib><creatorcontrib>Leonard, John M.</creatorcontrib><creatorcontrib>Cameron, D. William</creatorcontrib><title>Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4+ lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log10 copies/mL to below the detection limit of the assay (2.30 log10), and mean CD4+ lymphocyte count increased from 284 cells/mL to 413 cells/mL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8+ lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process.</description><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antigens</subject><subject>Antiretrovirals</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Blood plasma</subject><subject>CD28 Antigens - immunology</subject><subject>CD28 Antigens - metabolism</subject><subject>CD4 Lymphocyte Count</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell Division</subject><subject>Cytokines</subject><subject>Drug Therapy, Combination</subject><subject>Flow Cytometry</subject><subject>HIV</subject><subject>HIV - isolation & purification</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Protease Inhibitors - administration & dosage</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Immunity, Cellular</subject><subject>Interleukin-10 - metabolism</subject><subject>Interleukin-12 - metabolism</subject><subject>Interleukin-2 - metabolism</subject><subject>Leukocytes, Mononuclear - cytology</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Lymphocytes</subject><subject>Major Articles</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Phytohemagglutinins - immunology</subject><subject>Ritonavir - administration & dosage</subject><subject>Ritonavir - therapeutic use</subject><subject>RNA</subject><subject>RNA, Viral - isolation & purification</subject><subject>Saquinavir - administration & dosage</subject><subject>Saquinavir - therapeutic use</subject><subject>T lymphocytes</subject><subject>Viral Load</subject><subject>Viruses</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkV1rFDEUhgdR6lr1HwhBxLvRfGdyWZbWXakodS3iTchkMjbrTGabj-pe-8fNussWvPEqJzwP7-HlVNVzBN8g2PC3DDFM6YNqhhgRNeeIPKxmEGJco0bKx9WTGNcQQkq4OKlOJCNUcjSrfi_HTZju7Gh9As6DuR2G-oPtnE62A8txzN6Ci-xNcpMHXQ7OfwefprTTz3xy9SKP2u_FqbO9M856swXXLuQIVjc26M0W_HTpBly5NHl95wLYDIV91rfZ_f0_rR71eoj22eE9rb5cnK_mi_ry47vl_OyyNpSxVFsMtWwp0kZwjrVmlHSCtqyVreAd6nGnYWMlFrjtMZLQGE1II1qiCS2DJafV631uaXybbUxqdNGUwtrbKUclpBCYF_l_IuKUYcGbIr78R1xPOfhSQmFMJBQEyvs0E6YYg-3VJrhRh61CUO1up_a3K-KLQ1puR9sdtcOxCn914DoaPfRBe-PiUcMY8dLzPmYd0xSOmMCyCza7NfWeu5jsryPX4YfiggimFl-_KblikF7R9-qa_AHjB7lF</recordid><startdate>19980401</startdate><enddate>19980401</enddate><creator>Angel, Jonathan B.</creator><creator>Kumar, Ashok</creator><creator>Parato, Karl</creator><creator>Filion, Lionel G.</creator><creator>Diaz-Mitoma, Francisco</creator><creator>Daftarian, Pirouz</creator><creator>Pham, Ba'</creator><creator>Sun, Eugene</creator><creator>Leonard, John M.</creator><creator>Cameron, D. William</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19980401</creationdate><title>Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir</title><author>Angel, Jonathan B. ; Kumar, Ashok ; Parato, Karl ; Filion, Lionel G. ; Diaz-Mitoma, Francisco ; Daftarian, Pirouz ; Pham, Ba' ; Sun, Eugene ; Leonard, John M. ; Cameron, D. William</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-e20a9b41ac7662aa543d74b5b9b76d1f2da08e9272bf2190cca3387b3a34338e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antigens</topic><topic>Antiretrovirals</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Blood plasma</topic><topic>CD28 Antigens - immunology</topic><topic>CD28 Antigens - metabolism</topic><topic>CD4 Lymphocyte Count</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell Division</topic><topic>Cytokines</topic><topic>Drug Therapy, Combination</topic><topic>Flow Cytometry</topic><topic>HIV</topic><topic>HIV - isolation & purification</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Protease Inhibitors - administration & dosage</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Immunity, Cellular</topic><topic>Interleukin-10 - metabolism</topic><topic>Interleukin-12 - metabolism</topic><topic>Interleukin-2 - metabolism</topic><topic>Leukocytes, Mononuclear - cytology</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Lymphocytes</topic><topic>Major Articles</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Phytohemagglutinins - immunology</topic><topic>Ritonavir - administration & dosage</topic><topic>Ritonavir - therapeutic use</topic><topic>RNA</topic><topic>RNA, Viral - isolation & purification</topic><topic>Saquinavir - administration & dosage</topic><topic>Saquinavir - therapeutic use</topic><topic>T lymphocytes</topic><topic>Viral Load</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Angel, Jonathan B.</creatorcontrib><creatorcontrib>Kumar, Ashok</creatorcontrib><creatorcontrib>Parato, Karl</creatorcontrib><creatorcontrib>Filion, Lionel G.</creatorcontrib><creatorcontrib>Diaz-Mitoma, Francisco</creatorcontrib><creatorcontrib>Daftarian, Pirouz</creatorcontrib><creatorcontrib>Pham, Ba'</creatorcontrib><creatorcontrib>Sun, Eugene</creatorcontrib><creatorcontrib>Leonard, John M.</creatorcontrib><creatorcontrib>Cameron, D. William</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Angel, Jonathan B.</au><au>Kumar, Ashok</au><au>Parato, Karl</au><au>Filion, Lionel G.</au><au>Diaz-Mitoma, Francisco</au><au>Daftarian, Pirouz</au><au>Pham, Ba'</au><au>Sun, Eugene</au><au>Leonard, John M.</au><au>Cameron, D. William</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1998-04-01</date><risdate>1998</risdate><volume>177</volume><issue>4</issue><spage>898</spage><epage>904</epage><pages>898-904</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune function, and this may lead to favorable outcomes, independent of changes in CD4+ lymphocyte count. The effect of combination protease inhibitor therapy (ritonavir plus saquinavir) on functional measures of cell-mediated immunity in 41 HIV-infected patients from one center of a multicenter trial was investigated. After 24 weeks, median plasma virus load decreased from 4.74 log10 copies/mL to below the detection limit of the assay (2.30 log10), and mean CD4+ lymphocyte count increased from 284 cells/mL to 413 cells/mL. Proliferative responses to phytohemagglutinin developed in 21 of 34 patients in whom responses were absent at baseline. Increases were observed in interleukin-2, -12, and -10 production and in the expression of CD28 on CD8+ lymphocytes. Initiation of potent anti-HIV therapy results in a degree of immune restoration, suggesting that HIV-induced immune suppression is a dynamic and potentially reversible process.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>9534961</pmid><doi>10.1086/515244</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1998-04, Vol.177 (4), p.898-904 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79772634 |
| source | Jstor Complete Legacy; MEDLINE; Oxford Journals Online |
| subjects | AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antigens Antiretrovirals Antiviral agents Biological and medical sciences Blood Blood plasma CD28 Antigens - immunology CD28 Antigens - metabolism CD4 Lymphocyte Count CD8-Positive T-Lymphocytes - immunology Cell Division Cytokines Drug Therapy, Combination Flow Cytometry HIV HIV - isolation & purification HIV Infections - drug therapy HIV Infections - immunology HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - therapeutic use Humans Immunity, Cellular Interleukin-10 - metabolism Interleukin-12 - metabolism Interleukin-2 - metabolism Leukocytes, Mononuclear - cytology Leukocytes, Mononuclear - immunology Lymphocytes Major Articles Medical sciences Pharmacology. Drug treatments Phytohemagglutinins - immunology Ritonavir - administration & dosage Ritonavir - therapeutic use RNA RNA, Viral - isolation & purification Saquinavir - administration & dosage Saquinavir - therapeutic use T lymphocytes Viral Load Viruses |
| title | Improvement in Cell-Mediated Immune Function during Potent Anti-Human Immunodeficiency Virus Therapy with Ritonavir plus Saquinavir |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improvement%20in%20Cell-Mediated%20Immune%20Function%20during%20Potent%20Anti-Human%20Immunodeficiency%20Virus%20Therapy%20with%20Ritonavir%20plus%20Saquinavir&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Angel,%20Jonathan%20B.&rft.date=1998-04-01&rft.volume=177&rft.issue=4&rft.spage=898&rft.epage=904&rft.pages=898-904&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/515244&rft_dat=%3Cjstor_proqu%3E30108084%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223907309&rft_id=info:pmid/9534961&rft_jstor_id=30108084&rfr_iscdi=true |